Roth D M, Lefer D J, Hock C E, Lefer A M
Am J Physiol. 1985 Sep;249(3 Pt 2):H477-84. doi: 10.1152/ajpheart.1985.249.3.H477.
The purpose of the present investigation was to examine potential inotropic effects of leukotrienes C4 (LTC4) and D4 (LTD4) in relation to their potent coronary constricting effects. The experiments were carried out in isolated Langendorff perfused hearts and isolated electrically driven isometrically contracting papillary muscle preparations. Tissues from cat, rat, and guinea pig were used in the study. Both LTC4 and LTD4 at 50 ng/ml had no effect on papillary muscles isolated from the rat, guinea pig, or cat. These papillary muscles responded to known negative inotropic agents including pentobarbital sodium and methanol. In isolated hearts perfused under constant flow, both LTC4 and LTD4 at 50 ng/ml increased coronary perfusion pressure and decreased contractile force of the heart in all three species. In hearts perfused under constant pressure perfusion, both LTC4 and LTD4 decreased coronary flow with concomitant decreases in contractile force. The leukotriene antagonist, FPL 55712, blocked both the coronary constrictor and the cardiodepressant effects of both leukotrienes. Pentobarbital (100 micrograms/ml) significantly decreased cardiac contractile force without inducing coronary vasoconstriction. These findings demonstrate that LTC4 and LTD4 do not possess direct negative inotropic activity in cardiac muscles of these three species. However, LTC4 and LTD4 are potent coronary constrictors that can secondarily decrease myocardial contractile force via their coronary constrictor action.
本研究的目的是探讨白三烯C4(LTC4)和白三烯D4(LTD4)与其强大的冠状动脉收缩作用相关的潜在变力作用。实验在离体Langendorff灌注心脏和离体电驱动等长收缩乳头肌标本上进行。研究使用了猫、大鼠和豚鼠的组织。50 ng/ml的LTC4和LTD4对从大鼠、豚鼠或猫分离的乳头肌均无影响。这些乳头肌对包括戊巴比妥钠和甲醇在内的已知负性变力剂有反应。在恒流灌注的离体心脏中,50 ng/ml的LTC4和LTD4在所有三个物种中均增加了冠状动脉灌注压并降低了心脏的收缩力。在恒压灌注的心脏中,LTC4和LTD4均降低了冠状动脉血流量,同时收缩力也降低。白三烯拮抗剂FPL 55712阻断了两种白三烯的冠状动脉收缩作用和心脏抑制作用。戊巴比妥(100微克/毫升)显著降低心脏收缩力,但未诱导冠状动脉血管收缩。这些发现表明,LTC4和LTD4在这三个物种的心肌中不具有直接的负性变力活性。然而,LTC4和LTD4是强大的冠状动脉收缩剂,可通过其冠状动脉收缩作用继发降低心肌收缩力。